dme-mir-304: Dme-mir-304 is a microRNA that has been studied in relation to its correlation with other microRNAs, such as dme-mir-283 and dme-mir-12, in Drosophila melanogaster [PMC3150300]. Silencing dme-mir-304 has been shown to upregulate MBNL expression and rescue mis-splicing and muscle atrophy in a Drosophila model of myotonic dystrophy type 1 (DM1) [PMC8634727]. This upregulation of MBNL expression has also been achieved through other methods, such as using miRNA sponge constructs targeting dme-miR-277 and dme-mir-304 [PMC5090246]. Silencing of dme-miR-277 or dme-mir-304 has been found to increase Muscleblind levels and rescue its subcellular distribution in DM1 fly muscles [PMC5090246]. Furthermore, silencing of dme-miR-277 or dme-mir-304 derepresses muscleblind and improves survival of DM1 model flies [PMC5090246]. The binding sites of both dme-miR-277 and dme-mir-304 overlap in the 3' UTR region of the mblD isoform, which may explain the difference observed between in vivo and luciferase assays for mblD regulation by these microRNAs [PMC5090246]. Silencing of both miRNAs also rescues missplicing of CyP6W1, Fhos, and Serca1 transcripts [PMC6321436]. Overall, these findings highlight the potential therapeutic implications of targeting microRNAs like dme-mir-304 for the treatment of myotonic dystrophy type 1.